<DOC>
	<DOCNO>NCT02702401</DOCNO>
	<brief_summary>This study pembrolizumab ( MK-3475 ) participants previously systemically treat advanced hepatocellular carcinoma ( HCC ) . The primary objective study determine 1 ) Progression-Free Survival ( PFS ) 2 ) Overall Survival ( OS ) pembrolizumab plus best supportive care ( BSC ) compare placebo plus BSC . The primary hypothesis study : 1 ) pembrolizumab plus BSC prolongs PFS per Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 , assess blinded central image vendor compare placebo plus BSC , 2 ) pembrolizumab plus BSC improve OS compare placebo plus BSC .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) vs. Best Supportive Care Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma ( MK-3475-240/KEYNOTE-240 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has HCC diagnosis confirm radiology , histology cytology ( fibrolamellar mixed hepatocellular/cholangiocarcinoma subtypes eligible ) . Has Barcelona Clinic Liver Cancer ( BCLC ) Stage C disease , BCLC Stage B disease amenable locoregional therapy refractory locoregional therapy , amenable curative treatment approach . Has ChildPugh Class A liver score within 7 day first dose study drug . Has predict life expectancy &gt; 3 month . Has least one measurable lesion base Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 confirm blinded central image vendor . Has performance status 0 1 use Eastern Cooperative Oncology Group ( ECOG ) Performance Scale within 7 day first dose study drug . Has document objective radiographic progression treatment sorafenib intolerance sorafenib . Participants chronic infection Hepatitis C Virus ( HCV ) treat ( successfully treatment failure ) untreated allow study . In addition , participant successful HCV treatment allow long &gt; 4 week achieve sustained viral response ( SVR12 ) start study drug . Has control infection Hepatitis B Virus ( HBV ) . Is willing use adequate method contraception course study least 120 day longer base local regulation last dose study drug ( male female participant childbearing potential ) . Demonstrates adequate organ function . Is currently participate , participate study investigational agent receive study drug , herbal/complementary oral IV medicine , use investigational device within 4 week first dose study drug . Participants must also recover associated therapy ( i.e. , Grade ≤1 baseline ) adverse event ( AEs ) due prior therapy . Has receive sorafenib within 14 day first dose study drug . Has esophageal gastric variceal bleeding within last 6 month . Has clinically apparent ascites physical examination . Note : ascites detectable imaging study ARE allow . Portal vein invasion main portal ( Vp4 ) , inferior vena cava , cardiac involvement HCC base imaging . Has clinically diagnose hepatic encephalopathy last 6 month . Has solid organ hematologic transplant . Has prior systemic therapy HCC advance ( incurable ) set sorafenib , prior start study drug . Has know severe hypersensitivity ( &gt; Grade 3 ) pembrolizumab , active substance and/or excipients . Has active autoimmune disease require systemic treatment past 2 year ( i.e. , use diseasemodifying agent , corticosteroid , immunosuppressive drug . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study drug . Has receive locoregional therapy liver ( transcatheter chemoembolization [ TACE ] , transcatheter embolization [ TAE ] , hepatic arterial infusion [ HAI ] , radiation , radioembolization , ablation ) within 4 week prior first dose study drug . Has major surgery liver site within 4 week prior first dose study drug . Has minor surgery ( i.e. , simple excision , tooth extraction ) &lt; 7 day prior first dose study drug ( Cycle 1 , Day 1 ) . Has recover adequately ( i.e. , Grade ≤1 baseline ) toxicity and/or complication intervention prior start study drug . Has diagnose additional malignancy within 3 year prior first dose study drug exception curatively treat basal cell carcinoma skin , squamous cell carcinoma skin and/or curatively resect situ cancer . Has know history , evidence , central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has history noninfectious pneumonitis require steroid current pneumonitis . Has active infection require systemic therapy . Has know psychiatric substance abuse disorder would interfere cooperation requirement study . Is pregnant breastfeeding , expect conceive father child within project duration trial , start first dose study drug 120 day longer base local regulation last dose study drug . Has receive prior immunotherapy include antiprogrammed cell death1 ( antiPD1 ) , antiPDligand1 ( antiPDL1 ) , antiPDL2 agent , participant previously participate Merck pembrolizumab ( MK3475 ) study . Has know history human immunodeficiency virus ( HIV ) . Has dual active HBV infection HCV infection study entry . Has receive live vaccine within 30 day plan start study drug ( Cycle 1 , Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>